An announcement from Haleon PLC Sponsored ADR ( (HLN) ) is now available.
On April 17, 2025, Haleon PLC announced the purchase of 856,401 ordinary shares for cancellation as part of its share buyback program initiated on March 28, 2025. This transaction, completed on April 16, 2025, reflects the company’s strategic efforts to manage its capital structure and potentially enhance shareholder value. Following this buyback, Haleon’s registered share capital consists of 9,027,845,391 ordinary shares, with 9,023,765,186 shares holding voting rights, which stakeholders can use to assess their interests under regulatory guidelines.
Spark’s Take on HLN Stock
According to Spark, TipRanks’ AI Analyst, HLN is a Outperform.
Haleon’s strong financial performance, characterized by robust cash flow and stable profitability, is a key strength, complemented by positive technical indicators suggesting upward momentum. However, the stock’s valuation appears high, and recent earnings call highlights both opportunities in emerging markets and challenges like FX headwinds and product performance issues. These factors collectively position the stock at a solid yet cautious 73.1 score.
To see Spark’s full report on HLN stock, click here.
More about Haleon PLC Sponsored ADR
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a human touch. The company offers a diverse product portfolio across five major categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements (VMS). Its well-known brands include Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum, all built on trusted science and innovation.
YTD Price Performance: 7.63%
Average Trading Volume: 11,131,098
Technical Sentiment Signal: Sell
Current Market Cap: $45.14B
For a thorough assessment of HLN stock, go to TipRanks’ Stock Analysis page.